New Delhi, Oct 19 (PTI) Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market Sirolimus tablets, an immunosuppressant, in the American market.

The company's US-based subsidiary has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of PF Prism CV's Rapamune tablets, Glenmark Pharmaceuticals said in a statement.

Also Read | Google Assistant Driving Mode Rolled Out on Select Android Devices: Report.

Sirolimus tablets are prescribed for preventing rejection of kidney transplants either alone or with other medications.

According to IQVIA sales data for the 12-month period ending August 2020, the Rapamune achieved annual sales of around USD 119.7 million.

Also Read | Sony PlayStation 5 India Prices to Begin From Rs 39,990; Likely to Arrive Next Month Globally.

Glenmark said its current portfolio consists of 165 products authorised for distribution in the US marketplace and has 45 abbreviated new drug applications (ANDAs) pending with the USFDA for approval.

In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)